MBI on The Lead in Peds
Dr. Roger Packer, Senior Director of the Center for Neuroscience and Behavioral Medicine at Children’s National Hospital (USA), joined the The Lead in Peds podcast on September 24 to discuss recent advances in therapies for pediatric brain tumors. In the episode “Breaking Barriers: Emerging Therapies in Pediatric Brain Tumors,” Dr. Packer addressed the challenges of […]
MBI innovates once again with a new partnership: Einstein Hospital Israelita
The Medulloblastoma Initiative (MBI) announces a new partnership with Einstein Hospital Israelita, a collaboration that brings together two leading institutions in science and innovation with a shared purpose: to accelerate progress in the research and treatment of pediatric brain tumors. Recognized for its excellence in care, education, research, and social responsibility, Einstein combines tradition and […]
MBI mentioned by Exame
One of the most respected magazines in the country mentioned MBI in a report about scientific advances in the treatment of medulloblastoma. With more than 50 years of history, Exame is a national reference in economic, scientific, and innovation journalism. Since 2020, it has been part of the BTG Pactual Group, consolidating itself as one […]
From a Father’s Love, a Mission That Reached Brazil
Yesterday, October 5th, the story of our founder, Fernando Goldsztein, was featured on Fantástico — a brazilian Sunday night TV show with a huge audience that has been on the air for over 50 years. It was a powerful moment in which millions learned about a mission born from love and courage. The MBI emerged […]
MBI on CNN
The Medulloblastoma Initiative (MBI) was featured on the CNN Brasil website, in a report that highlights the impact of our innovative model for accelerating science. In just 30 months, we have raised more than $11 million, established partnerships with 16 leading institutions in the United States, Canada, and Germany, and accelerated discoveries that previously took […]
Race for Every Child 2025: join the MBI team – There’s No Time to Lose
On October 18, the Race for Every Child, organized by Children’s National Hospital in Washington, D.C., will take place. The event brings together thousands of people in a 5K run/walk — and you can join from anywhere in the world. In 2024, the MBI team — No Time to Lose earned first place in fundraising, […]
Fox News recognizes MBI’s contribution in the fight against medulloblastoma
International recognition marks an important milestone for the MBI. Fox News, through anchor Bret Baier — former chief White House and Pentagon correspondent — highlighted MBI’s mission to accelerate scientific discoveries and transform the lives of thousands of children. In the special report, the network emphasized the urgency of advancing research on medulloblastoma and pointed […]
Gold September: for a cure for childhood cancer
Gold September is the global awareness month for childhood cancer. Gold represents the value of children and reminds us of the importance of early diagnosis—which increases survival chances and allows for less aggressive treatments As pediatric oncologist Dr. Juliana Dal Ponte Bitencourt explains, “Early diagnosis enables the disease to be detected at initial stages, increasing […]
Lemonade for a cure: the sweetness of childhood in service of science
Small gestures can spark big transformations. For the third year in a row, the Lemonade for a Cure project has shown how children’s solidarity can power science. Kennedy, just 7 years old, set up her lemonade stand several times over the summer. With the support of her family and community, she didn’t just reach her […]
Two Nature group articles recognize MBI’s contribution to science
Researchers from the Cure Group Four Consortium, supported by MBI and focused on high-impact investigations into pediatric brain tumors, have recently published two articles in the Nature group. The articles feature the co-authorship of scientists from the Cure Group Four, whose research is backed by MBI and dedicated to groundbreaking studies on pediatric brain tumors. […]